Table 3.
Relationship Between Immunocheckpoint Markers and Clinicopathological Characteristics
| Characteristics | CTLA4 in TILs |
PD-1 in TILs |
PD-L1 in TILs |
PD-L1 in Tumor Cells |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative |
Positive |
P | Negative |
Positive |
P | Negative |
Positive |
P | Negative |
Positive |
P | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||||
| Age | ||||||||||||
| ≤ 57 | 53 (53) | 38 (52.1) | .9021 | 55 (48.2) | 25 (59.5) | .2113 | 68 (51.9) | 19 (54.3) | .8025 | 83 (51.9) | 5 (71.4) | .3105 |
| > 57 | 47 (47) | 35 (47.9) | 59 (51.8) | 17 (40.5) | 63 (48.1) | 16 (45.7) | 77 (48.1) | 2 (28.6) | ||||
| Histological type | ||||||||||||
| IDC | 83 (83) | 62 (84.9) | .9142 | 98 (86) | 35 (83.3) | .4111 | 108 (82.5) | 31 (88.6) | .2273 | 135 (84.4) | 5 (71.4) | .0287 |
| ILC | 10 (10) | 7 (9.6) | 7 (6.1) | 5 (11.9) | 16 (12.2) | 1 (2.8) | 17 (10.6) | 0 (0) | ||||
| Other | 7 (7) | 4 (5.5) | 9 (7.9) | 2 (4.8) | 7 (5.3) | 3 (8.6) | 8 (5) | 2 (28.6) | ||||
| Tumor size (cm) | ||||||||||||
| ≤ 2 cm | 63 (64.3) | 48 (65.8) | .8423 | 72 (63.7) | 23 (54.8) | .309 | 86 (65.6) | 18 (52.9) | .1714 | 99 (62.3) | 6 (85.7) | .2079 |
| > 2 cm | 35 (35.7) | 25 (34.2) | 41 (36.3) | 19 (45.2) | 45 (34.4) | 16 (47.1) | 60 (37.7) | 1 (14.3) | ||||
| Lymph node status | ||||||||||||
| Negative | 57 (58.2) | 48 (65.8) | .3132 | 70 (61.9) | 26 (28) | <.0001 | 74 (100) | 25 (73.5) | <.0001 | 95 (60.1) | 5 (71.4) | .5493 |
| Positive | 41 (41.8) | 25 (34.2) | 43 (38.1) | 67 (72) | 0 (0) | 9 (26.5) | 63 (39.9) | 2 (28.6) | ||||
| Histological grade | ||||||||||||
| G1 | 11 (11.2) | 4 (5.6) | .0103 | 8 (7.1) | 3 (7.5) | .164 | 13 (10.1) | 1 (7.1) | .1903 | 13 (8.3) | 1 (14.3) | .2979 |
| G2 | 64 (65.3) | 35 (49.3) | 69 (61.6) | 18 (45) | 80 (62) | 12 (85.8) | 91 (58.4) | 2 (28.6) | ||||
| G3 | 23 (23.5) | 32 (45.1) | 35 (31.3) | 19 (47.5) | 36 (27.9) | 1 (7.1) | 52 (33.3) | 4 (57.1) | ||||
| Receptor status | ||||||||||||
| ER-negative (≤10%) | 18 (18.2) | 10 (13.9) | .4539 | 18 (16.1) | 9 (21.4) | .4362 | 21 (16.2) | 7 (20.6) | .5407 | 27 (17.1) | 2 (28.6) | .4348 |
| ER-positive (> 10%) | 81 (81.8) | 62 (86.1) | 94 (83.9) | 33 (78.6) | 109 (83.8) | 27 (79.4) | 131 (82.9) | 5 (71.4) | ||||
| PgR-negative (≤ 10%) | 32 (32.3) | 28 (38.9) | .3744 | 41 (36.6) | 16 (38.1) | .8647 | 43 (33.1) | 16 (47.1) | .1304 | 55 (34.8) | 4 (57.1) | .2277 |
| PgR-positive (> 10%) | 67 (67.7) | 44 (61.1) | 71 (63.4) | 26 (61.9) | 87 (66.9) | 18 (52.9) | 103 (65.2) | 3 (42.9) | ||||
| MIB1 | ||||||||||||
| Negative (≤20%) | 70 (77.7) | 71 (74.7) | .5289 | 78 (69.6) | 24 (57.1) | .1441 | 96 (73.8) | 16 (47.1) | .0028 | 110 (69.6) | 3 (42,9) | .1358 |
| Positive (> 20%) | 29 (29.3) | 24 (25.3) | 34 (30.4) | 18 (42.9) | 34 (26.2) | 18 (52.9) | 48 (30.4) | 4 (57.1) | ||||
| HER2/neu | ||||||||||||
| Negative (0,1+) | 85 (85.9) | 59 (83.1) | .622 | 94 (83.9) | 34 (82.9) | .882 | 113 (87.6) | 23 (67.6) | .0054 | 133 (84.7) | 4 (57.1) | .0543 |
| Positive (3+) | 14 (14.1) | 12 (16.9) | 18 (16.1) | 7 (17.1) | 16 (12.4) | 11 (32.4) | 24 (15.3) | 3 (42.9) | ||||